Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations
Opioid use disorder (OUD) in pregnant women has increased significantly in recent years. Maintaining these women on sublingual (SL) buprenorphine (BUP) is an evidence-based practice but BUP-SL is associated with several disadvantages that an extended-release (XR) BUP formulation could eliminate. The National Drug Abuse Treatment Clinical Trials Network (CTN) is conducting an intent-to-treat, two-arm, open-label, pragmatic randomized controlled trial, Medication treatment for Opioid-dependent expectant Mothers (MOMs), to compare mother and infant outcomes of pregnant women with OUD treated with BUP-XR, relative to BUP-SL.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Theresa Winhusen, Michelle Lofwall, Hendr ée E. Jones, Christine Wilder, Robert Lindblad, Davida M. Schiff, Scott Wexelblatt, Stephanie Merhar, Sean M. Murphy, Shelly F. Greenfield, Mishka Terplan, Elisha M. Wachman, Frankie Kropp, Jeff Theobald, Mitra L Source Type: research